ONTRACK'S TEST
Our urine test is designed to reduce the burden on patients and healthcare systems by supporting more informed decisions on prostate biopsy and active surveillance of indolent prostate cancer, while decreasing associated costs.
THE WORKFLOW
DOCTOR
DIAGNOSTIC
LAB
PATIENT
Urine Sample
HOSPITAL / CLINIC / PHARMACY
INNOVATING DIAGNOSTICS FOR BETTER OUTCOMES
ONtrack's urine test is designed to benefit patients, medical doctors, and healthcare systems alike.
It aims to reduce the burden on patients, improve diagnostic accuracy, and lower costs. Learn more about ONtrack's test and its potential impact on patients, medical doctors, and the healthcare system.
​
Developed in ELISA format, ONtrack's urine test is designed to run on standard automated platforms already present in clinical laboratories — including Abbott, Roche, Siemens, and Beckman Coulter — requiring no sample processing or stabilization and enabling seamless integration into existing clinical workflows.
​
ONtrack's urine test is currently under development and is not yet available on the market.
Patients
ONtrack's urine test is designed to reduce the diagnostic burden on patients through its non-invasive nature and simple application, improving quality of life by reducing the number of individuals who need to undergo unnecessary prostate biopsies and their related side-effects.
Urologists & family doctors
Medical doctors will be provided with an innovative non-invasive diagnostic tool to identify individuals at risk of prostate cancer and, most importantly, to ensure that men with clinically significant prostate cancer are not missed and are referred for biopsy at the right time.
Health Insurances - Healthcare system
The adoption of ONtrack's urine test, at significantly lower cost than a prostate biopsy, combined with a substantial reduction in unnecessary biopsies, is expected to meaningfully reduce overall healthcare costs related to the diagnosis and monitoring of prostate cancer.